News for Agent

Daily business news: funding, M&A, launches

Partnerships

Merck and Isomorphic Labs Launch AI Research Collaboration on Oncology Target

By ·

Key takeaways

  • Merck and Isomorphic Labs will collaborate to discover small-molecule candidates against an oncology target of strategic importance.
  • Isomorphic Labs will apply its IsoDDE drug design engine to Merck's proprietary data sets, while Merck handles preclinical, clinical, manufacturing and commercialization work.
  • Isomorphic Labs receives an upfront payment, milestone payments and tiered royalties, plus an option to co-fund development for elevated royalties.
  • The collaboration follows Isomorphic Labs' $5 billion Series C round led by Sequoia Capital and Greenoaks.

Merck and Isomorphic Labs announced a research collaboration to discover small-molecule candidates against an oncology target of strategic importance, with Isomorphic Labs receiving an upfront payment, milestone payments and tiered royalties on net sales. TradingView published the announcement on November 19, 2026.

How the Merck and Isomorphic Labs Work Will Be Split

Under the collaboration, Isomorphic Labs will perform in silico predictions and deliver molecular designs using its proprietary drug design engine, IsoDDE, incorporating select high-quality proprietary data sets supplied by Merck for the purpose of the collaboration. Merck will be responsible for preclinical and clinical development, as well as manufacturing and commercialization of any products derived from the collaboration. Isomorphic Labs also receives an option to co-fund development activities in return for elevated royalties.

STAT reported that the oncology target is undisclosed and that the partnership follows Isomorphic's $5 billion funding round. Bloomberg reported on November 17, 2026 that Isomorphic Labs raised $5 billion in a Series C round led by Sequoia Capital and Greenoaks, with Andreessen Horowitz and earlier investors Thrive Capital, GV and CapitalG also participating.

George Addona, senior vice president and head of discovery, preclinical development and translational medicine at Merck Research Laboratories, said: "The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions." Sarah Skerratt, chief research officer at Isomorphic Labs, said the collaboration will apply "our world-leading drug design engine to unlock significant discovery progress." Isomorphic Labs was founded in 2021 and is led by CEO Sir Demis Hassabis and President Max Jaderberg.

Merck's Earlier AI and Oncology Deals

According to akta.pro company records, Merck entered a multi-target drug discovery collaboration with Protillion Biosciences in June 2026 to access the Prot-MaP AI on-chip antibody discovery platform, with up to $510 million in milestone payments to Protillion across multiple therapeutic programs. The same records show that in June 2026 the FDA approved Welireg (belzutifan) in combination with Keytruda for adjuvant renal cell carcinoma based on the Phase 3 LITESPARK-022 trial showing a 28% reduced risk of disease recurrence.

Merck's Recent Pipeline and Board Moves

On November 18, 2026, TradingView reported that Merck ended development of the BTK inhibitor MK-1026, the drug that was the main reason it acquired ArQule for $2.7 billion in 2019. On November 13, 2026, Longevity.Technology reported that Merck began ENHANCE-3, a Phase 3 trial of ensifentrine (Ohtuvayre) for COPD that will follow 2,136 patients for a year, with first patients enrolling in the US. TradingView reported on November 18, 2026 that Thomas H. Glocer will retire from Merck's board at the May 2027 annual meeting and Douglas M. Baker, Jr. will become independent lead director effective January 1, 2027.

Companies in this story

Sources

Machine-readable: Markdown · JSON